News & Media
Learn more about the latest happenings at Otsuka. Select to see US news or read our press releases. You can also stay up to date with our global news in the link below.
Otsuka Pharmaceutical Development & Commercialization, Inc., announces that it has entered a three-year collaboration with Holmusk Inc., a global data science and digital health company building the world’s largest real-world evidence (RWE) platform for behavioral health.
The Sozosei Foundation, a charitable foundation funded by Otsuka America Pharmaceutical, Inc., awarded grants to 10 organizations committed to the decriminalization of mental illness by ensuring the effective implementation of 988 as the nationwide mental health crisis hotline that goes live in July, 2022 and by increasing access to mental healthcare in communities across the United States.
Akebia Therapeutics, Inc. and Otsuka Pharmaceutical Co., Ltd. today announced that the U.S. Food and Drug Administration (FDA) accepted for filing the New Drug Application (NDA) for vadadustat for the treatment of anemia due to chronic kidney disease (CKD) in both adult patients on dialysis and adult patients not on dialysis.
Amidst COVID-19, Mental Health Leaders, Policymakers Explore Innovations and Policy Solutions to Strengthen Access to Care for People Living with Serious Mental Illness
WASHINGTON, DC – May 12, 2021 – Otsuka America Pharmaceutical, Inc. (Otsuka), a global leader in developing solutions to meet unmet mental health needs, today hosted its third-annual Advancing Mental Health Policy: BetterTogether Forum. This live, virtual event brought together more than 300 elected officials, thought leaders and stakeholders from across the mental health community to discuss the impact of COVID-19 on people living with mental illness and policies for strengthening equitable access to behavioral health care.